{"id":"W2093009907","doi":"10.1056/nejmoa1114287","title":"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1703,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Placebo; Medicine; Multiple sclerosis; Internal medicine; Clinical endpoint; Regimen; Placebo-controlled study; Gastroenterology; Randomized controlled trial; Double blind; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1492640750751503,"score_gpt":0.3816020995237962,"score_spread":0.2323380244486459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}